4-(2-噻吩基) 苯甲酰氯 | 181132-70-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-噻吩基) 苯甲酰氯
• 中文别名: 4-(2-噻吩基)苯甲酰氯
• 英文名称: 4-(thiophen-2-yl)benzoyl chloride
• 英文别名: 4-(2-Thienyl)Benzoyl Chloride；4-thiophen-2-ylbenzoyl chloride
• CAS: 181132-70-7
• 化学式: C₁₁H₇ClOS
• mdl: MFCD02681905
• 分子量: 222.695
• InChiKey: WWIBCNCKODGBTI-UHFFFAOYSA-N

物化性质

• 熔点：
  113 °C

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2934999090
• 危险品运输编号：
  UN 3261

SDS

Name:	4-(2-Thienyl)benzoyl chloride 97% Material Safety Data Sheet
Synonym:
CAS:	181132-70-7

Section 1 - Chemical Product MSDS Name:4-(2-Thienyl)benzoyl chloride 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
181132-70-7	4-(2-Thienyl)benzoyl chloride	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns. Lachrymator (substance which increases the flow of tears).
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 181132-70-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 116 - 118 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H7ClOS
Molecular Weight: 222.69

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 181132-70-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(2-Thienyl)benzoyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 181132-70-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 181132-70-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 181132-70-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2-噻吩基) 苯甲酰氯 在 2-甲氧基吡啶 、 三氟甲磺酸酐 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 19.0h， 生成 N,N-diethyl-4-(thiophen-2-yl)-N'-tosylbenzohydrazonamide
  参考文献：
  名称：

  从叔酰胺中快速获得3-氨基吲唑

  摘要：

  从容易获得的起始原料开发了两步合成结构多样的3-氨基吲唑。该序列包括通过化学选择性Tf 2 O介导的叔酰胺活化并随后添加亲核酰肼的一锅合成氨基hydr 。然后，这些前体参与分子内无配体的Pd催化的CH氨基化反应。通过这种方法合成的氮杂杂环通过随后的脱保护/官能化反应进一步多样化。

  DOI：

  10.1021/acs.orglett.5b00765
• 作为产物：
  描述：

  4-噻吩-2-硼酸甲酯 在 草酰氯 、 水 、 N,N-二甲基甲酰胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 4-(2-噻吩基) 苯甲酰氯
  参考文献：
  名称：

  CoIII催化的芳酰胺的CH和N-H键之间的异腈插入/酰基迁移

  摘要：

  异腈的一般有效和位点选择性钴催化的插入C-H和芳基酰胺的N-H键的通过C-H键活化和醇的分子内辅助反-amidation是证明。这种直接的方法克服了强螯合基团的存在所带来的限制。首次实现了对Co III腈配合物B的分离，以了解其反应机理。

  DOI：

  10.1002/chem.201705710

文献信息

• Piperazine and homopiperazine compounds
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20030153556A1

  公开（公告）日：2003-08-14

  Compounds are provided having a piperazine or homopiperazine ring which are useful in the treatment of thrombosis.

  提供了具有哌嗪或同源哌嗪环的化合物，这些化合物在治疗血栓症方面很有用。
• NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20130289033A1

  公开（公告）日：2013-10-31

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R 1 , R 2 , R 4 , R 5 , R 6 , E, n, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , B, R 8 , and m are as defined in the claims.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样生成特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明进一步涉及包括所述新型化合物的药物组合物以及制备所述新型化合物的方法。这些化合物的公式为(A1)，其中R1、R2、R4、R5、R6、E、n、Y1、Y2、Y3、Y4、Y5、B、R8和m如权利要求中所定义。
• Tricyclic benzazepine vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：US05849735A1

  公开（公告）日：1998-12-15

  Tricyclic compound of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and process for preparing such compounds.

  三环化合物的一般公式I：##STR1##，如本文所述，具有V.sub.1和/或V.sub.2受体的拮抗剂活性，并在体内表现出抗利尿激素拮抗剂活性，使用这些化合物治疗以肾水过度重吸收为特征的疾病的方法，以及制备这些化合物的方法。
• [EN] NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF<br/>[FR] NOUVELLES N-ACYL-5,6,7,8-TÉTRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZINES 8-SUBSTITUÉES CHIRALES UTILISÉES COMME ANTAGONISTES SÉLECTIFS DES RÉCEPTEURS NK-3, COMPOSITION PHARMACEUTIQUE, PROCÉDÉS DESTINÉS À ÊTRE UTILISÉS DANS DES TROUBLES À MÉDIATION PAR LE RÉCEPTEUR NK-3 ET LEUR SYNTHÈSE CHIRALE
  申请人：EUROSCREEN SA

  公开号：WO2013050424A1

  公开（公告）日：2013-04-11

  The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

  本发明涉及公式I的新化合物及其在治疗治疗中的应用。该发明还涉及使用N-sp3保护基对5,6,7,(8-取代)-四氢-[1,2,4]三唑并[4,3-a]吡嗪进行新的手性合成。该发明还提供了用于合成公式I化合物的中间体。
• [EN] BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS<br/>[FR] PETITES MOLÉCULES CONTENANT DU BORE ET UTILISABLES EN TANT QU'AGENTS ANTIPROTOZOAIRES
  申请人：ANACOR PHARMACEUTICALS INC

  公开号：WO2011019618A1

  公开（公告）日：2011-02-17

  This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. The compounds have the following formula: wherein X is selected from the group consisting of substituted phenyl, substituted or unsubstituted heteroaryl and unsubstituted cycloalkyl; R3a is selected from the group consisting of H1 unsubstituted C1 or C2 or C3 or C4 or C5 or C6 alkyl and unsubstituted C3 or C4 or C5 or C6 cycloalkyl; R3b is selected from the group consisting of H, unsubstituted C1 or C2 or C3 or C4 or C5 or C6 alkyl and unsubstituted C3 or C4 or C5 or C6 cycloalkyl; with the proviso that R3a and R3b, along with the atom to which they are attached, are optionally joined to form a 3 or 4 or 5 or 6 membered ring, with the proviso that R3a and R3b cannot both be H, or a salt thereof.

  这项发明提供了用于治疗原虫感染的新化合物，包含这些化合物的药物组合物，以及这些化合物与至少一种额外治疗有效剂的组合物。这些化合物具有以下结构式：其中X选自取代苯基、取代或未取代杂环芳基和未取代环烷基的组；R3a选自H1未取代的C1或C2或C3或C4或C5或C6烷基和未取代的C3或C4或C5或C6环烷基的组；R3b选自H、未取代的C1或C2或C3或C4或C5或C6烷基和未取代的C3或C4或C5或C6环烷基的组；但R3a和R3b，以及它们连接的原子，可选地结合形成3、4、5或6元环，但R3a和R3b不能同时为H，或其盐。